3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Glioma
2
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
14
Gemcitabine
6
Filgrastim
6
fludarabine
5
Methotrexate
5
Leucovorin
5
Granulocyte Colony-Stimulating Factor
5
Zoledronic Acid
4
Temozolomide
4
Mesna
4
Irinotecan
4
Ifosfamide
4
Etoposide
4
Cisplatin
4
Carboplatin
4
pembrolizumab
3
fludarabine phosphate
3
Doxorubicin
3
Biopsy
3
tanespimycin
2
poly ICLC
2
pegfilgrastim
2
lorukafusp alfa
2
liposomal doxorubicin
2
dinutuximab
2
cabozantinib
2
belinostat
2
Topotecan
2
Thalidomide
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Osteosarcoma
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled